REPLY
2.11.2021 09:32:11 CET | Business Wire | Press release
Reply’s new trend report , which was conducted with the data-driven trend platform SONAR, shows up how Artificial Intelligence (AI) will play a crucial role in the continuous improvement of the future Customer Experience (CX). The SONAR trend platform - enabled by AI – analyses more than 50 million sources like international expert media, scientific publications, and patent applications from recent years to identify upcoming opportunities and trends that will be impacted the most by technological development.
According to the report, AI will further improve the efficiency and effectiveness of marketing, leading to better results and providing opportunities for brands to create entirely new experiences for customers. The use of AI will exponentially increase data collection capabilities to better understand consumer values and attitudes on a large scale. At the same time, improved data management that combines the increasing volumes of structured and unstructured data will enhance the ability of AI to better predict the future.
In all areas of marketing - whether in marketing research, marketing strategy or marketing action - AI will have a significant impact. The analysis identifies the core trends and the strongest enabling technologies supporting the different use cases, as correlated through expert media analysis.
In marketing research, two trends will be accelerated by AI: Sentiment Analysis and Visual Listening . Currently, Sentiment Analysis mostly offers a binary perspective on consumer relation to a brand based on positive or negative reactions online. However, AI-based concepts like Emotion AI and Natural Language Processing can identify nuances in consumer sentiment, helping brands understand consumer emotions at scale and in real-time. Similarly, Visual Listening technologies like Computer Vision, Deep Reinforcement Learning and MLOps allow brands to understand how they are perceived in visual contexts.
In terms of marketing strategy, the trends of Consumer Segmentation and Marketing Effectiveness Modelling (MEM) are also set to evolve rapidly thanks to AI. With Customer Segmentation, companies can use AI to create more dynamic and specific consumer segments, enabling brands to target individuals more precisely across a variety of digital channels and touchpoints, better addressing their needs. MEM, as the active tracking of campaign performance and ROI, is also rapidly advancing by using AI to capture and process exponentially increasing volumes of data. Soon, AI-enabled MEM will have ubiquitous applications not only tracking the past and present but also making predictions based on machine learning techniques.
Within the field of marketing action, Chatbots and Virtual Assistants and Personalised Customer Experiences are growing rapidly with AI. With Chatbots and Virtual Assistants, brands can offer one-to-one customer experiences at scale engaging with consumer in real-time. Personalised Customer Experiences are also enabled by AI using Natural Language Processing and MLOps to provide bespoke recommendations, customised messaging, and unique offers, helping establish stronger loyalty through meaningful interactions.
“The design of contemporary customer experiences is no longer possible without the use of Artificial Intelligence. This applies to all phases: marketing research, marketing strategy, and marketing action. AI can be used to create an IT landscape to make informed predictions and give marketing teams perspective on where they can take their customer experiences in the future. External analysts such as Luenendonk also share this vision and rank Reply as a market leader in their recently published market study on digital experience service providers," sums up Filippo Rizzante, CTO at Reply.
The Trend Report on AI and CX is part of a series on the topics of Logistics , New Interfaces , Automotive & mobility e-commerce , 5G .
Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211102005039/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom